Official NSE Sectoral Index·As of 21 Sept 2026
NIFTY PHARMA Valuation Multiples
Benchmark index representing pharmaceutical formulations, active pharmaceutical ingredients (APIs), generic manufacturing, and global healthcare suppliers.
Official NSE Indices
Sector PE RatioOfficial NSE Indices
41.8427.6% above 10Y Median
Consolidated TTM earnings multiple of constituent equities.
Observation Date21 Sept 2026
Price to Book (PB)Official NSE Indices
5.08
Price to book value of net assets across sector holdings.
Observation Date21 Sept 2026
Dividend YieldOfficial NSE Indices
0.52%
Cash dividend yield distributed by constituent companies.
Observation Date21 Sept 2026
vs NIFTY 50 PEDerived · Nifty Valuation Desk
+111.4%Premium vs Benchmark
Relative to consolidated NIFTY 50 PE multiple (19.79).
Observation Date21 Sept 2026
NIFTY PHARMA Historical Valuation
PEOfficial historical valuation series. Benchmark 10Y median: 32.80
Date:21 Sep 2026
Price:—
P/E:41.84x
P/B:5.08x
Div Yield:0.52%
Single Merged Chart: Left Scale = Price (₹) | Right Scale = P/E Multiple (x)Synchronized Time Axis & Crosshair
NSE Verified Daily Observations·Historical data available since Jan 2000 (26+ years of verified daily history)
290 observations loaded
10Y Statistical Range
21.00 – 46.50
Historical trough and peak observations recorded since 2016.
Historical Median PE
32.80
Current PE of 41.84 trades at 27.6% above median.
Key Fundamental Driver
US FDA Regulatory Approvals, Domestic Formulation Growth, and Generic Price Realization
Primary industry variable driving multiple expansion/contraction.
NIFTY PHARMA Constituent Equities (20 Stocks)
Official constituent basket with individual valuation and profile access.
Data coverage: Complete 10-year official historical dataset (2016–2026). Ingested daily from official NSE Indices feeds.Read Methodology →